SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-038850
Filing Date
2018-06-20
Accepted
2018-06-20 18:07:17
Documents
2
Period of Report
2018-06-20

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 8967
2 POA DOCUMENT poa.txt EX-24.3_797608 3583
  Complete submission text file 0001209191-18-038850.txt   13968
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Issuer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address
Kirk Christopher J. (Reporting) CIK: 0001744253 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38542 | Film No.: 18910360